Antihistone antibodies in scleroderma.
BACKGROUND
Antihistone antibodies (AHA) are usually considered the serological marker of drug-induced lupus erythematosus, but recently they have been found in patients with systemic scleroderma (SSc) and morphea.


OBJECTIVE
We determined AHA in 43 patients with SSc, 4 patients with overlap syndrome and 11 with morphea.


CONCLUSIONS
AHA were demonstrated in 41.8% of the SSc patients and in 36.3% of the morphea patients. Only 1 patient with overlap syndrome had AHA. Our SSc patients with AHA had frequent cardiac and renal involvements suggesting a prognostic value of AHA. In our morphea patients AHA did not correlate with clinical features.
Parodi
A
A
Department of Dermatology, University of Genoa, Italy.
Drosera
M
M
Barbieri
L
L
Rebora
A
A
D000328:Adult; D000368:Aged; D017153:Antibodies, Anticardiolipin / Q000032:analysis; D000974:Antibodies, Antinuclear / Q000032:analysis; D001323:Autoantibodies / Q000032:analysis*; D009202:Cardiomyopathies / Q000473:pathology; D004264:DNA Topoisomerases, Type I / Q000276:immunology; D005260:Female; D006657:Histones / Q000276:immunology*; D006801:Humans; D007674:Kidney Diseases / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012594:Scleroderma, Localized / Q000276:immunology; D012595:Scleroderma, Systemic / Q000276:immunology* / Q000473:pathology
D017153:Antibodies, Anticardiolipin; D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D006657:Histones; D004264:DNA Topoisomerases, Type I